-
Something wrong with this record ?
Effects of parenteral administration of enrofloxacin on electrocardiographic parameters in hospitalized dogs
Carlos Fernando Agudelo Ramírez, Peter Scheer, Jaroslava Tomenendálová
Language English Country Czech Republic
Document type Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1978
Open Access Digital Library
from 1978-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1978
- Keywords
- repolarizace, QT interval,
- MeSH
- Bacterial Infections drug therapy prevention & control MeSH
- Electrocardiography * drug effects MeSH
- Enrofloxacin * antagonists & inhibitors pharmacology adverse effects MeSH
- Fluoroquinolones pharmacology classification adverse effects MeSH
- Injections MeSH
- Dogs MeSH
- Cardiac Electrophysiology MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Dogs MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
The effect of enrofloxacin on the QT interval of the electrocardiogram was studied in 30 hospitalized dogs. The experimental group (n = 15) received enrofloxacin parenterally (subcutaneously) at a dose of 5 mg/kg twice daily and amoxicillin-clavulanate intravenously at a dose of 22 mg/kg three times daily. The control group (n = 15) received only amoxicillin-clavulanate. Electrocardiography was carried out for 5 min once daily for 6 days. The QT interval was corrected by four different formulae. No differences were found between the two groups or within each group for the duration of the study. On the last day of the study the average QT interval for the control and experimental groups was 213.2 ms and 202.9 ms, respectively. Enrofloxacin did not cause prolongation of the QT or corrected QT intervals. We can conclude that the parenteral administration of enrofloxacin in non-cardiac dogs does not adversely affect the electrocardiographic indicators (no prolongation of the QT or corrected QT interval) and does not induce ventricular arrhythmias. Parenteral use of enrofloxacin is thus safe and effective in non-cardiac dogs.
References provided by Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17018677
- 003
- CZ-PrNML
- 005
- 20190123122309.0
- 007
- cr|cn|
- 008
- 170601s2012 xr fs 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2754/avb201281040409 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Ramírez, Carlos Fernando Agudelo $7 _AN091777 $u University of Veterinary and Pharmaceutical Sciences Brno, Faculty of Veterinary Medicine, Department of Internal Medicine, Clinic of Dog and Cat Diseases, Brno, Czech Republic
- 245 10
- $a Effects of parenteral administration of enrofloxacin on electrocardiographic parameters in hospitalized dogs / $c Carlos Fernando Agudelo Ramírez, Peter Scheer, Jaroslava Tomenendálová
- 504 __
- $a Literatura
- 520 3_
- $a The effect of enrofloxacin on the QT interval of the electrocardiogram was studied in 30 hospitalized dogs. The experimental group (n = 15) received enrofloxacin parenterally (subcutaneously) at a dose of 5 mg/kg twice daily and amoxicillin-clavulanate intravenously at a dose of 22 mg/kg three times daily. The control group (n = 15) received only amoxicillin-clavulanate. Electrocardiography was carried out for 5 min once daily for 6 days. The QT interval was corrected by four different formulae. No differences were found between the two groups or within each group for the duration of the study. On the last day of the study the average QT interval for the control and experimental groups was 213.2 ms and 202.9 ms, respectively. Enrofloxacin did not cause prolongation of the QT or corrected QT intervals. We can conclude that the parenteral administration of enrofloxacin in non-cardiac dogs does not adversely affect the electrocardiographic indicators (no prolongation of the QT or corrected QT interval) and does not induce ventricular arrhythmias. Parenteral use of enrofloxacin is thus safe and effective in non-cardiac dogs.
- 650 12
- $a enrofloxacin $x antagonisté a inhibitory $x farmakologie $x škodlivé účinky $7 D000077422
- 650 _2
- $a fluorochinolony $x farmakologie $x klasifikace $x škodlivé účinky $7 D024841
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a psi $7 D004285
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a bakteriální infekce $x farmakoterapie $x prevence a kontrola $7 D001424
- 650 12
- $a elektrokardiografie $x účinky léků $7 D004562
- 650 _2
- $a srdeční elektrofyziologie $7 D054849
- 650 _2
- $a injekce $7 D007267
- 653 00
- $a repolarizace
- 653 00
- $a QT interval
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Scheer, Peter, $d 1973- $7 xx0033760 $u St. Anne's Hospital Brno - ICRC, Brno, Czech Republic; University of Veterinary and Pharmaceutical Sciences Brno, Faculty of Veterinary Medicine, Department of Physiology, Brno, Czech Republic
- 700 1_
- $a Tomenendálová, Jaroslava $7 _AN091778 $u University of Veterinary and Pharmaceutical Sciences Brno, Faculty of Veterinary Medicine, Department of Physiology, Brno, Czech Republic
- 773 0_
- $t Acta veterinaria Brno $x 0001-7213 $g Roč. 81, č. 4 (2012), s. 409-414 $w MED00172332
- 856 41
- $u https://actavet.vfu.cz/ $y domovská stránka časopisu
- 910 __
- $a ABA008 $b online $y 4 $z 0
- 990 __
- $a 20170331101410 $b ABA008
- 991 __
- $a 20190123122531 $b ABA008
- 999 __
- $a ok $b bmc $g 1230929 $s 979529
- BAS __
- $a 3 $a 4
- BMC __
- $a 2012 $b 81 $c 4 $d 409-414 $i 0001-7213 $m Acta veterinaria Brno $x MED00172332
- LZP __
- $c NLK185 $d 20190123 $a NLK 2017-11/pk
